Wright Medical Group Sees Broader Q1 Loss

Zacks

Wright Medical Group, Inc. (WMGI) posted a wider adjusted net loss of $16.6 million or 34 cents per share for the first quarter of 2014 compared with a loss of $3.3 million or 8 cents in the same quarter of 2013. However, the loss was narrower than the Zacks Consensus Estimate of a loss of 42 cents.

Net loss totaled $30.3 million or 62 cents per share compared with a net loss of $4.9 million or 12 cents per share in the year-ago quarter. Reported net loss stood at $30.4 million or 63 cents per share in the quarter compared with earnings of $8.4 million or 20 cents per share in the year-ago quarter.

Despite reporting dismal fiscal 2014-first-quarter results, shares of WMGI jumped almost 8.2% following the earnings release to close at $30.00 yesterday.

Revenues

Revenues in the quarter went up 26.2% (26% in constant currency) to $71.1 million, edging past the Zacks Consensus Estimate of $70.0 million. The revenue growth was driven by strong sales in the Foot and Ankle product line.

On a geographic basis, international sales were strong with a 63.4% rise in revenues to $22.1 million. Revenues from the domestic market improved 14.5% to $49.0 million in the quarter.

Segment Details

Global revenues from the Foot and Ankle business moved up 31.1%, both in reported and constant currency, to $46.0 million, on synergies from the Solana Surgical and OrthoPro acquisitions. Domestic revenues grew 19.3% to $33.1 million whereas, international revenues surged 76.0% (or 74% in constant currency) to $12.9 million.

Global revenues from the Biologics business went up 14.5% (or 16% in constant currency) on the back of growth in international markets mainly driven by sales in China and continued growth of Augment Bone Graft in Australia. Domestic revenues rose 6.6% to $11.1 million while international revenues increased 40.3% (or 47% in constant currency) to $4.5 million.

Revenues from the Upper Extremities business grew 6.9% globally, both in reported and constant currency, to $6.5 million. Excluding the impact of the Biotech International acquisition completed in November last year, Upper Extremities revenues declined 11% during the quarter. Domestic revenues decreased 11.2% to $3.7 million whereas international revenues increased 45.0%, both in reported and constant currency, to $2.8 million.

Global revenues in the Other product line escalated 96.6% (or 92% in constant currency) to $2.9 million. Domestic revenues soared 138.5% to $1.0 million while international revenues grew 79.6% (or 74% in constant currency) to $1.9 million.

Margins

Gross profit rose 25.9% to $53.6 million, primarily on lower inventory reserve requirements. However, gross margin decreased marginally by 20 basis points (bps) to 75.5% from 75.7% a year ago.
 
Adjusted operating loss increased substantially by 227.0% to $14.5 million, while adjusted operating (loss) margin rose 1,250 bps to 20.4% from 7.9% a year ago.

Adjusted EBITDA was a negative $6.2 million compared to a positive $1.4 million in the same quarter last year.

Financial Position

WMGI exited the quarter with cash and cash equivalents of $343.9 million, up 28.6% from $267.5 million as of Mar 31, 2013, due to the completion of the MicroPort, Solana and OrthoPro transactions. Long-term obligations rose 6.3% to $277.7 million from $261.3 million as of Mar 31, 2013.

During the quarter, cash flow from operations deteriorated significantly to the use of $27.2 million from the use of $5.2 million a year ago. Capital expenditures more than doubled to $7.8 million from $3.7 million a year ago.

Outlook

For 2014, WMGI anticipates adjusted loss per share, including stock-based compensation, in the range of $1.28-$1.38. The current Zacks Consensus Estimate of a loss of $1.32 lies within the guided range.

For 2014, WMGI narrowed its revenue guidance to the range of $308–$312 million from the prior range of $305–312 million. The revised guidance represents a year-over-year rise of 27–29% (including Solana, OrthoPro and Biotech acquisitions). The current Zacks Consensus Estimate of $310 million lies within the projected range.

The expected range of revenues incorporates the effect of short-term dis-synergies due to the closure of transactions with MicroPort, Biotech International, Solana Surgical and OrthoPro, and includes a negative year-over-year currency impact of 1%.

WMGI reiterated its previously announced adjusted EBITDA guidance in the range of negative $20.0 million to negative $15.0 million for 2014.

Zacks Rank

Currently, WMGI carries a Zacks Rank #3 (Hold). Some better-ranked medical product stocks include Cardica Inc. (CRDC), Enzymotec Ltd. (ENZY) and Mead Johnson Nutrition Company (MJN). All the three stocks carry a Zack Rank #2 (Buy).

Read the Full Research Report on WMGI
Read the Full Research Report on CRDC
Read the Full Research Report on MJN
Read the Full Research Report on ENZY


Zacks Investment Research

Rates

View Comments (0)